Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
about
Pathophysiology of diabetic retinopathyA small-molecule screen for enhanced homing of systemically infused cellsProtein kinase C mechanisms that contribute to cardiac remodellingIndolocarbazole natural products: occurrence, biosynthesis, and biological activity.Protein kinase C-β inhibitor treatment attenuates hepatic ischemia and reperfusion injury in diabetic ratsNeed for quality improvement in renal systematic reviews.Protein Kinase C Inhibitors as Modulators of Vascular Function and their Application in Vascular DiseaseThe life and death of protein kinase C.Diabetic neuropathy: cellular mechanisms as therapeutic targets.Knockout mouse models of insulin signaling: Relevance past and futureInhibition of PKCβ2 overexpression ameliorates myocardial ischaemia/reperfusion injury in diabetic rats via restoring caveolin-3/Akt signaling.Designing of Protein Kinase C β-II Inhibitors against Diabetic complications: Structure Based Drug Design, Induced Fit docking and analysis of active site conformational changesEffect of phorbol esters on the macrophage-mediated biodegradation of polyurethanes via protein kinase C activation and other pathways.Protein kinase C isozymes and their selectivity towards ruboxistaurin.Insights into the structural requirements of PKCβII inhibitors based on HQSAR and CoMSIA analyses.Blood-brain barrier breakdown promotes macrophage infiltration and cognitive impairment in leptin receptor-deficient mice.PKC-β activation inhibits IL-18-binding protein causing endothelial dysfunction and diabetic atherosclerosis.Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1).Protein kinase C inhibitor prevents renal apoptotic and fibrotic changes in response to partial ureteric obstruction.
P2860
Q26865897-FDF7FD85-49F4-4855-812F-8EA91A6AC871Q27321219-5C5C16E8-4522-443D-A4BF-79364727978CQ28075729-D3E68CC8-5873-4209-A32E-2A8A877AABC7Q34583547-EC3D2A5C-92F3-40F0-BF5B-193E47611FE7Q36524139-446BB613-A30A-46B0-BD43-0EF7021120E7Q36736617-F9FA367E-7E6E-4CD0-BD37-58E8ADB6F551Q36748065-8BF97AE1-F795-4E8F-AE39-B6B6D328A008Q37239605-125E8F53-FC2F-4535-8DE8-4A63F2DC6884Q37930962-6332FE8F-EAFC-4C72-B32E-27D13F1D0877Q38205763-8D31E7C8-CE90-4634-B93F-368EDE931162Q38890008-2B6CB20E-35CF-4C23-99FB-52258297D18AQ42239965-36C44D80-B065-4FFD-817D-6ECF0251AC20Q46116703-A21B9068-0419-41D0-8395-53581D80C734Q46794973-E44067A0-2D07-499D-B804-6B4AAB2C9CA9Q46825961-657C12AB-7FFA-4BA4-B86A-B3E7A753701CQ47168123-CBEA6EBA-EF73-4700-8E7C-91DFC50B3554Q52956251-C330A865-9B78-486A-96DA-BE0A2154C047Q54232641-F0F3EB70-8141-4450-A777-8E5405C82142Q54545123-CE10E7E9-4E83-4859-A2E2-C06B1E0090F1
P2860
Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Ruboxistaurin, a protein kinas ...... s microvascular complications.
@ast
Ruboxistaurin, a protein kinas ...... s microvascular complications.
@en
type
label
Ruboxistaurin, a protein kinas ...... s microvascular complications.
@ast
Ruboxistaurin, a protein kinas ...... s microvascular complications.
@en
prefLabel
Ruboxistaurin, a protein kinas ...... s microvascular complications.
@ast
Ruboxistaurin, a protein kinas ...... s microvascular complications.
@en
P2093
P2860
P356
P1476
Ruboxistaurin, a protein kinas ...... s microvascular complications.
@en
P2093
Ann C Scates
Christina A Taulien
Jason A Goebel
Michael J Cooney
Moahad Dar
Scott V Joy
Srilaxmi Bearelly
P2860
P304
P356
10.1345/APH.1E572
P407
P577
2005-09-13T00:00:00Z